Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01922661 · ClinicalTrials.gov registry record · Phase 1
Single Ascending-dose Study of the Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Subjects
A Phase 1 study of Allergy, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 2
- Study locations
NCT01922661: Completed Phase 1 study of Allergy, sponsored by Regeneron Pharmaceuticals.
NCT01922661 is a Phase 1 study of Allergy that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 24 participants, below the 331-participant average among 15 other Allergy trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01922661, a Phase 1 study of Allergy, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 2
- Study locations
Study Summary
The primary objective of the study is to assess the safety and tolerability of single ascending doses of subcutaneously (SC) administered REGN1908-1909 in allergic, adult subjects.
Primary Outcome
The primary endpoint is to assess treatment-emergent adverse events (TEAEs) from day 1 through day 113 (end of study).
Conditions Studied
Interventions
- OTHER placebo
- DRUG REGN1908-1909
Study Locations (2)
Kansas
- - Overland Park
Maryland
- - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2013-08 |
| Est. Completion | 2014-05 |
| Phase | Phase 1 |
What the finished NCT01922661 record still lists
NCT01922661 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 331-participant average among 15 other Allergy trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Allergy appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT01922661 reports a single indexed study location in Kansas, Maryland.
Frequently Asked Questions
What is clinical trial NCT01922661 about?
NCT01922661 is a clinical study titled "Single Ascending-dose Study of the Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Subjects". The primary objective of the study is to assess the safety and tolerability of single ascending doses of subcutaneously (SC) administered REGN1908-1909 in allergic, adult subjects.
What is the current status of trial NCT01922661?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2013-08. Estimated completion is 2014-05.
What conditions does trial NCT01922661 study?
This clinical trial studies the following conditions: Allergy.
What interventions are being tested in trial NCT01922661?
The interventions under investigation include: placebo (OTHER), REGN1908-1909 (DRUG).
Who is sponsoring clinical trial NCT01922661?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01922661 being conducted?
This trial has 2 study locations across Kansas, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01922661's enrollment target sits among peer trials
24 13th of 15 higher than 3 of 15 other Allergy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Allergy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sublingual Cockroach Safety in Adults With Cockroach Allergy & Perennial Allergic Rhinitis With or Without Asthma
COMPLETED · Phase 1
-
In Vitro Basophil Responsiveness to Allergen Challenge After Gamma-tocopherol Supplementation in Allergic Asthmatics
COMPLETED · Phase 1
-
Understanding Allergies and Sensitizations in Healthy and Allergic Individuals
RECRUITING
-
The Nonirritating Concentrations of Midazolam, Ketamine, and Ondansetron
RECRUITING · Phase 4
-
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
RECRUITING · Phase 3
-
Childhood Allergy and the Neonatal Environment
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia